Ruanyun Edai Signs Exclusive Malaysian Healthcare AI Licensing Deal With BioNexus Gene Lab
Bitget2026/10/30 13:02- Ruanyun Edai Technology signed an agreement granting BioNexus Gene Lab an exclusive Cogni AI license for Malaysian healthcare.
- The 10-year license is renewable for up to 20 years, with a 10% royalty on qualifying technology receipts and no guaranteed revenue.
- Contractual license consideration is US$3.5 million, payable through 410,000 BioNexus common shares valued at US$520,700 at October 2, 2026, closing prices.
- A separate exchange involves 150,000 BioNexus common shares for 500,000 Ruanyun ordinary shares, with no cash payment.
- Closing remains subject to testing acceptance and approvals; either non-defaulting party may terminate if closing misses March 31, 2027, unless extended.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Crypto prices
More
